Antigen-specific Vaccines, Glioma, Malignant, Individualized Treatment
Conditions
Brief summary
The primary objective of this study is to assess the safety and tolerability, feasibility of the NeoPep Vaccine in newly diagnosed glioblastoma (GB) patients.
Detailed description
This is a signelcenter, open-label, single arm, first-in-human phase I trial to investigate the safety, feasibility and immune response of the novel NeoPep Vaccine in patients with newly diagnosed GB. Primary Endpoints: Determine the safety and tolerability profile of NeoPep Vaccine1and 2 when administered with immunomodulators and Stupp standard treatment Secondry Endpoints: 1. Descriptive analysis of induced T-cell immune responses after vaccinations with NeoPep Vaccine1and 2 drug products plus immunomodulators and Stupp standard treatment. 2. Overall survival with NeoPep Vaccine1 and 2 plus immunomodulator in newly diagnosed glioma in patients treated with standard Stupp. 3. Progression-free survival with NeoPep Vaccine1 and 2 plus immunomodulator in newly diagnosed glioma in patients treated with standard Stupp. After the standard chemoradiotherapy with TMZ has been completed, Vaccination was initiated 14 days before the first maintenanceTMZ cycle. It starts with the first NeoPep Vaccine1, followed by additional NeoPep Vaccine2 at a later time point and ends with the Last Endpoint Evaluation Visit (LEEV) of a patient.
Interventions
DRUGNeoPep Vaccine1 plus Poly-ICLC
NPVAC1： NPVAC1 drug products are composed of 5 peptides from the HCMV warehouse， NPVAC1 vaccine will be applied before maintenance TMZ cycles after completion of chemoradiation therapy (CRT). Beginning on day 14 before the first maintenance TMZ cycle, patients will receive 7 vaccinations with NPVAC1 drug products during 6 weeks. 400 μg per peptide per vial are used. Poly-ICLC: Poly-ICLC（500ug）will be used as immunomodulator with all vaccinations.
DRUGNeoPep Vaccine2 plus Poly-ICLC
NPVAC2： NPVAC2 will be ready for use 2 months after enrollment, as these peptides have to be newly synthesized for each patient following identification of the mutanome and corresponding mutated peptides in the HLA ligandome. NPVAC2 drug products are composed 20 peptides de novo synthesized for an individual patient. Patients will be repeatedly vaccinated with NPVAC2 drug products beginning on day 33 of the 6 maintenance TMZ cycle.Patients will receive 9 vaccinations within 12 weeks. 400 μg per peptide per vial are used. Poly-ICLC: Poly-ICLC（500ug）will be used as immunomodulator with all vaccinations.
Sponsors
Hangzhou NeoVax Biotechnology Co. Ltd.
Shanghai 10th People's Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Ability of subject to understand and the willingness to sign written informed consent for study participation; 2. Patients with newly diagnosed high-grade glioma confirmed by histopathological and imaging evaluation; 3. Gross total resection (as defined by less than 1 cm2 residual tumor mass on the largest perpendicular axes in post-operative scan taken within 48 h post-surgery; standard MRI conformable to the present national and international guidelines is sufficient)； 4. At least 0.5 g tumor tissue freshly cryopreserved during surgery，and could provide adequate amounts of PBMC； 5. Patient is a candidate for and willing to receive standard CRT with TMZ followed by maintenance TMZ cycles; 6. Age 18-70; 7. Life expectancy \> 9 months; 8. KPS≥70; 9. Sufficient tumor tissue samples and peripheral blood samples can be obtained for sequencing analysis, or whole exome sequencing and RNA sequencing of tumor tissue samples and peripheral blood samples have been obtained, and the sequencing data meet the prediction requirements; 10. Consent of women and men of reproductive age to use adequate and effective contraception during clinical trials; 11. Normal laboratory values for hematology, liver and renal function (serum creatinine).In detail the following values apply as inclusion criteria: 1. White blood cell count (WBC) ≥3.0×109/L； 2. Absolutely neutrophil count≥1.0×109/L； 3. Platelet count≥80×109/L； 4. Hemoglobin content≥90g/L； 5. Serum creatinine≤1.5 ULN or Creatinine clearance rate≥40 mL/min; 6. TBil(total bilirubin)≤1.5 x ULN; 7. Aspartic transaminase(AST)≤2.5x ULN or Alanine aminotransferase（ALT）≤2.5x ULN；Patients with liver metastases must have ≤5x ULN; 8. Blood coagulation function :INR≤1.5x ULN；pT and APTT≤1.5x ULN; 9. Urine protein\< 2 +;if Urine protein≥2+,24-hour urinary protein must be less than 1g.
Exclusion criteria
1. Patients treated with immunosuppressive agents (e.g., cyclosporin CsA, tacrolimus, rapamycin, azathioprine, etc.) within the previous month; Other immunotherapy within 3 months; 2. History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 5 years unless the patient has been disease-free for 5 years; 3. Participated in other clinical trials within 30 days prior to screening; 4. Have a history of severe allergy or allergic constitution; 5. Patients who have undergone splenectomy; 6. Persons with primary or secondary immunodeficiency diseases (e.g. AIDS);Patients with autoimmune diseases; 7. Patients who received multiple oral, intramuscular, or intravenous corticosteroids within 30 days before the first dose; However, patients who received a single oral, intramuscular, or intravenous dose of dexamethasone of 5mg or less (or another hormone of equivalent potency) 14 days before the first dose were allowed; Allow inhaled corticosteroids to treat respiratory insufficiency (e.g., chronic obstructive pulmonary disease), or topical steroids; 8. Patients with uncontrollable seizures, central nervous system disorders, or psychotic loss of cognition; 9. Uncontrolled central nervous system metastases; 10. Patients had a history of chronic alcohol or drug abuse in the 6 months before screening; 11. With unstable systemic disease, such as active infection, liver cirrhosis, chronic renal failure, severe chronic pulmonary disease, unstable hypertension, unstable angina pectoris, congestive heart failure, myocardial infarction within one year, etc. ; 12. According to this procedure, the number of candidate neoantigens that can be used to make personalized vaccines is less than 20; 13. The investigator did not consider it appropriate to participate in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and toleration | Continously for about 40 weeks plus follow-up | Determine the safety and tolerability profile of NeoPep Vaccine1and 2 when administered with immunomodulators and Stupp standard treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| T-cell immune response | till 24 months of vaccination | Descriptive analysis of induced T-cell immune responses after vaccinations with NeoPep Vaccine1and 2 drug products plus immunomodulators and Stupp standard treatment. |
| Overall survival(OS) | till 24 months of vaccination | Overall survival with NeoPep Vaccine1 and 2 plus immunomodulator in newly diagnosed glioma in patients treated with standard Stupp. |
| Progression-free survival（PFS） | till 12 months of vaccination | Progression-free survival with NeoPep Vaccine1 and 2 plus immunomodulator in newly diagnosed glioma in patients treated with standard Stupp. |
Countries
China
Contacts
Primary ContactLei Li, Phd
Outcome results
None listed